Figure 4.
In EAC patients with no adverse features of tumor biology, CCL3, CCL4, IL-1α, and IL-12/IL-23p40 levels were higher in serum, with the contrary evident for Tie2 and VEGF. Groups were divided according to adverse features of tumor biology, with groupings of 0 adverse features, 1–2 adverse features or 3–4 adverse features. Data were analyzed by ANOVA (Kruskal–Wallis test with Dunn’s multiple comparisons). * p < 0.05. ** p < 0.01. IL = Interleukin, VEGF = Vascular Endothelial Growth Factor.
